Mashup Score: 1
OncLiveNeoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr
See more from OncLive.com
Neoadjuvant treatment with tremelimumab & durvalumab was well tolerated in dMMR and MSI-H, EBV–negative GEJ adenocarcinoma, according to findings from the phase 2 INFINITY trial. #oncology #GI23 #stomachcancer https://t.co/43WygRQspe - view on twitter